- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03604601
Analysis of the Curative Effect of Salvage Surgery on Recurrent Laryngeal Carcinoma
July 20, 2018 updated by: GengLong Liu, First Affiliated Hospital, Sun Yat-Sen University
Analysis of the Curative Effect of Salvage Surgery on Recurrent Laryngeal Carcinoma: A Single-institutional Experience
Early laryngeal cancer can be treatment by laser surgery or radiotherapy, intermediate and advanced laryngeal carcinoma mainly surgical treatment.
Laryngeal cancer is at risk of recurrence after treatment, whether in surgery, laser or radiotherapy.
The recurrence rate of laryngeal cancer is about 10% reported at home and abroad.
Local pain, ulcers, breathing and eating difficulties caused by recurrent laryngeal cancer seriously reduce the quality of life of patients and seriously endanger their lives.
Therefore, head and neck surgeons are required to make every effort to give them saving treatment in order to improve their quality of life.
Prolong the patient's life.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
medical records and extracted information including age, gender, initial treatment modality of glottis cancer, recurrence time, recurrence site, histopathology, tumor grade according to World Health Organization (WHO) grade and tumor stage.
Stages were defined according to the American Joint Committee on Cancer (AJCC) staging system.
Study Type
Observational
Enrollment (Actual)
54
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
patients with recurrent laryngeal squamous cell carcinoma
Description
Inclusion Criteria:
- more than 18 years,
- patients with recurrent glottic laryngeal squamous cell carcinoma undergoing salvage surgery
Exclusion Criteria:
- postoperative radiotherapy and chemotherapy
- loss to follow-up
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
overall survival (OS)
Time Frame: Follow up 5 years
|
The overall survival rate was calculated with Kaplan-Meier method.
|
Follow up 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Genglong Liu, First Affiliated Hospital, Sun Yat-Sen University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2016
Primary Completion (Actual)
June 1, 2018
Study Completion (Actual)
June 1, 2018
Study Registration Dates
First Submitted
July 13, 2018
First Submitted That Met QC Criteria
July 20, 2018
First Posted (Actual)
July 27, 2018
Study Record Updates
Last Update Posted (Actual)
July 27, 2018
Last Update Submitted That Met QC Criteria
July 20, 2018
Last Verified
July 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Respiratory Tract Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Otorhinolaryngologic Diseases
- Laryngeal Diseases
- Carcinoma
- Recurrence
- Laryngeal Neoplasms
Other Study ID Numbers
- recurrent laryngeal carcinoma
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.